Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Eli Lilly (NYSE ... Novo Nordisk and Hims & Hers Health. Lower prices, raise market share. It's as simple as that -- and good enough for a 2.6% stock price bump. The Motley Fool Stock Advisor ...

The price a stock ... for a top growth stock to come down to a P/E of 20 or less, you may end up waiting forever and missing out on the opportunity completely. For years, Eli Lilly has been ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Eli Lilly (NYSE:LLY) recently announced its plans ... import tariffs on medications under the Trump administration. LLY stock has fared well so far this year, up around 20%. At its current levels ...

The stock has bounced back since lowering ... From a valuation perspective, Lilly trades at a forward price-to-earnings (P/E) ratio of 37 times 2025 analyst estimates but has a price/earnings ...

Learn More » All of this has helped Lilly's revenue climb in the double digits in recent quarters and the stock price to take off. The shares have advanced more than 200% over the past three years.

Lilly could obtain approval for a weight loss pill that would unlock even more growth. Investors should never ignore valuations when picking stocks. The price a stock trades at can drastically ...